Prime Minister Narendra Modi on Friday held a review of India’s vaccination strategy amid indications that the fast-developing Oxford-AstraZeneca shot may be eligible for emergency use authorisation in India as early as next month. The PM reviewed the aspects of emergency use authorisation and manufacture and procurement of medicine. As the results of Phase 3 trials arrive, regulators will speedily examine these for according authorisation for use. Adar Poonawala of Serum Institute, which is manufacturing the vaccine in India, has indicated that it can approach the Indian regulator soon after the UK partner reveals the phase 3 trial results.